Rohto Pharmaceutical Co.,Ltd.
Stock Price Chart
2026/01/16 UpdatedPrice Trend
2026/01/16 UpdatedPrice & Trading Details
2026/01/16 UpdatedPRICE
TRADING
Analyst Recommendations 9 analysts
Updated 2026/01/11Shareholder Composition
Updated 2026/01/11Major Holders
Updated 2026/01/11| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
MFS SERIES TRUST X-MFS International Intrinsic Value Fund
|
10.4M | -0.50% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
2.9M | +1.01% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
1.9M | +2.77% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
1.3M | +0.81% | |
|
MFS Varbl INSURANCE TRT II-MFS Intl Intrinsic Value PORT.
|
662.0K | 0.00% | |
|
EQ Advisors Trust-EQ/MFS International Intrinsic Value Portfolio
|
630.7K | +1.69% |
Dividend History 4Years Growth
Updated 2026/01/11| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥41 | +32.3% |
| 2024 | ¥31 | +29.2% |
| 2023 | ¥24 | +17.1% |
| 2022 | ¥21 | +41.4% |
| 2021 | ¥15 | - |
Financial Performance
2026/01/11 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥199,646M | ¥238,664M | ¥270,840M | ¥308,625M |
| Gross Profit | ¥116,170M | ¥137,421M | ¥157,285M | ¥174,939M |
| Operating Income | ¥29,019M | ¥33,964M | ¥40,052M | ¥38,943M |
| Pretax Income | ¥28,122M | ¥34,537M | ¥41,714M | ¥43,280M |
| Net Income | ¥21,127M | ¥26,377M | ¥30,936M | ¥31,006M |
| EPS | ¥92.34 | ¥115.29 | ¥135.21 | ¥135.44 |
| Operating Margin | 14.54% | 14.23% | 14.79% | 12.62% |
| Balance Sheet | ||||
| Total Assets | ¥274,876M | ¥309,677M | ¥346,175M | ¥421,875M |
| Total Equity | ¥178,398M | ¥209,568M | ¥246,323M | ¥260,093M |
| Total Liabilities | ¥96,478M | ¥100,109M | ¥99,852M | ¥161,782M |
| Cash | ¥72,791M | ¥79,951M | ¥89,210M | ¥77,161M |
| Interest-bearing Debt | ¥21,383M | ¥11,693M | ¥10,494M | ¥50,223M |
| Equity Ratio | 64.90% | 67.67% | 71.16% | 61.65% |
| D/E Ratio | 0.12 | 0.06 | 0.04 | 0.19 |
| Cash Flow | ||||
| Operating CF | ¥27,250M | ¥30,924M | ¥34,245M | ¥36,917M |
| Investing CF | -¥16,406M | -¥13,176M | -¥16,317M | -¥89,170M |
| Financing CF | ¥3,470M | -¥16,199M | -¥13,784M | ¥35,319M |
| Free CF | ¥15,922M | ¥21,016M | ¥25,333M | ¥26,356M |
| Efficiency | ||||
| ROE | 11.84% | 12.59% | 12.56% | 11.92% |
| ROA | 7.69% | 8.52% | 8.94% | 7.35% |
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥2,917
Rating Score: 2.10 (Based on 9 analysts)
※1=Strong Buy, 5=Strong Sell
Rohto PharmaceuticalLtd's (TSE:4527) Dividend Will Be Increased To ¥22.00 - simplywall.st ↗
Company Information
About
Rohto Pharmaceutical Co.,Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide. The company provides eye care products, such as eye drops, care for contact lenses, and eye wash; and facial care products comprising face wash, lotions, and creams. It also offers medicine and medicated products for skin, lip balms, sunscreens, functional cosmetics, etc.; medicine for internal use, such as digestive and herbal medicines; regenerative medicines; OTC pharmaceutical products, including ophthalmic, dermatological, gastrointestinal, and diagnostic drugs, as well as Chinese herbal medicines, and supplements. In addition, the company operates beauty counters that provide beauty and health services; and manufactures and sells diagnostic reagents, as well as provides investment management services; and contract development and manufacturing services. The company was formerly known as Yamada Pharmaceutical and changed its name to Rohto Pharmaceutical Co.,Ltd. in September 1949. The company was founded in 1899 and is headquartered in Osaka, Japan.
